

## Supplementary Materials

**Table S1.** Seropositivity of myositis antibodies in patients with CAG and control patients.

Myositis-related antibody	AIG (n = 45)	NAIG (n = 109)	Control (n = 201)	Total (n = 355)
Ro52 n (%)	1 (2.2)	1 (0.9)	3 (1.5)	5 (1.4)
OJ	0	2 (1.9)	0	2 (0.6)
EJ	0	0	0	0
PL12	0	1 (0.9)	4 (2.0)	5 (1.4)
PL7	1 (2.2)	1 (0.9)	2 (1.0)	4 (1.1)
SRP	1 (2.2)	2 (1.9)	0	3 (0.9)
Jo1	1 (2.2)	2 (1.9)	1 (0.5)	4 (1.1)
PM75	2 (4.4)	5 (4.7)	9 (4.5)	16 (4.5)
PM100	0	3 (2.8)	2 (1.0)	5 (1.4)
Ku	0	0	2 (1.0)	2 (0.6)
SAE1	0	1 (0.9)	0 (0.0)	1 (0.3)
NXP2	1 (2.2)	0	0	1 (0.3)
MDA5	0	0	1 (0.5)	1 (0.3)
TIF1g	1 (2.3)	0	1 (0.5)	2 (0.6)
Mi2a	0	0	0	0
Mi2b	0	1 (0.95)	1 (0.5)	2 (0.6)
At least one antibody equivocal or positive n (%)	7 (14.3)	15 (15.6)	26 (12.9)	48 (13.6)
At least one positive antibody n (%)	4 (8.9)	6 (5.5)	9 (4.4)	19 (5.3)

AIG, Autoimmune Gastritis; NAIG, Non-autoimmune Gastritis; Seropositivity for myositis-associated antibodies: negative <10, equivocal > 10, positive >25. For every antibody presented seropositivity is for >10, values are presented as n (%).

**Table S2** ANA concentrations in patients with CAG and control patients.

ANA	AIG (n = 45)	NAIG (n = 109)	p-value	Control (n = 201)	Total (n = 355)
Negative	21 (46.7)	64 (59.8)		125 (62.5)	210 (59.7)
Equivocal	3 (6.7)	12 (11.2)		21 (10.5)	36 (10.2)
Weakly positive	10 (22.2)	14 (13.1)		21 (10.5)	45 (12.8)
positive	10 (22.2)	13 (12.1)		26 (12.8)	49 (13.9)
Strongly positive	1 (2.2)	4 (3.7)		7 (3.5)	12 (3.4)
All positive results combined	<b>21 (46.7)</b>	<b>31 (29.0)</b>	<b>0.033</b>	54 (27.0)	106 (30.1)

AIG, Autoimmune Gastritis; NAIG, Non-autoimmune Gastritis; ANA, anti-nuclear antibodies; ANA results: negative dilution <1:80; equivocal 1:80; weakly positive 1:160; positive for 1:320 or 1:640; strongly positive for the dilution ≥1:1280. Values are presented as n (%).